Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder
- Registration Number
- NCT02466386
- Lead Sponsor
- Shire
- Brief Summary
The purpose of this study is to evaluate the long-term safety of SPD489 administered as a daily morning dose (5, 10, 15, 20, and 30 mg/day) in preschool children diagnosed with Attention-deficit/Hyperactivity Disorder (ADHD).
- Detailed Description
This study is a long-term, open-label study where participants who participated in an antecedent SPD489 study (SPD489-211 \[NCT02402166\] or SPD489-347 \[NCT03260205\]) or through direct enrollment. Participants entering into this study will be classified as either a roll-over participants or a direct-enrolled participants.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 113
-
Participant is male or female aged 4-5 years inclusive at the time of consent from antecedent studies SPD489-211 or SPD489-347 or at the time of consent if directly enrolled.
-
Before completing any study-related procedures, participant's parent(s) or legally authorized representative (LAR) must provide signature of informed consent, and there must be documentation of assent (if applicable) by the participant indicating that the participant is aware of the investigational nature of the study. The participant's parent(s) or LAR should understand that the required procedures and restrictions are being conducted in accordance with the International Council of Harmonisation (ICH) Good Clinical Practice (GCP) Guideline E6 (1996), any updates or revisions, and applicable federal or local regulations.
-
Participant and parent(s)/LAR are willing and able to comply with all of the testing and requirements defined in the protocol, including oversight of morning dosing. Specifically, the parent/LAR should be available at approximately 7:00AM (+2 hours) to dispense the dose of investigational product for the duration of the study.
-
Roll-over participant from antecedent SPD489-347 study:
a. Participant completed the antecedent study (SPD489-347)
-
Direct enrolled participants must meet antecedent study inclusion criteria, as listed below
- Participant must meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV-TR) criteria for a primary diagnosis of ADHD (any subtype) based on a detailed psychiatric evaluation conducted by a sponsor-approved clinician
- Participant has an attention-deficit/hyperactivity disorder rating scale- IV (ADHD-RS-IV) Preschool Version total score at the Baseline Visit (Visit 0) of greater than equals to (>=) 28 for boys and >= 24 for girls.
- Participant has a Clinical Global Impressions - Severity of Illness (CGI-S) score >=4 at the Baseline Visit (Visit 0).
- Participant has a Peabody Picture Vocabulary Test, Fourth Edition standard score of >=70 at the Screening Visit (Visit -1).
- Participant has undergone an adequate course of non-pharmacological treatment based on investigator judgment or the participant has a severe enough condition to consider enrollment without undergoing prior non-pharmacological treatment, based on investigator judgment.
- Participant has, in the opinion of the investigator, participated in a structured group activity (eg, preschool, sports, Sunday school) so as to assess symptoms and impairment in a setting outside the home.
- Participant has lived with the same parent(s) or guardian for >=6 months.
-
Participant was terminated from an antecedent SPD489 study for non-compliance and/or experienced a serious adverse event (SAE) or adverse event (AE) resulting in termination.
-
Participant is required to or anticipates the need to take medications that have central nervous system effects or affect performance, such as, but not limited to, sedating antihistamines and decongestant sympathomimetics, or monoamine oxidase inhibitors. Stable use of bronchodilator inhalers is not exclusionary.
-
Participant has a concurrent chronic or acute illness (such as, but not limited to, severe allergic rhinitis or an infectious process requiring antibiotics), disability, or other condition that might confound the results of safety assessments conducted in the study or that might increase risk to the participant. Similarly, the participant will be excluded if he or she has any additional condition(s) that, in the investigator's opinion, would prohibit the participant from completing the study or would not be in the best interest of the participant. The additional condition(s) would include any significant illness or unstable medical condition that could lead to difficulty complying with the protocol. Mild, stable asthma is not exclusionary.
-
Participant has a documented allergy, hypersensitivity, or intolerance to amphetamine or to any excipients in the investigational product.
-
Participant has a known family history of sudden cardiac death or ventricular arrhythmia.
-
Participant has a blood pressure measurement >= 95th percentile for age, sex, and height at the screening visit (Visit -1) or the baseline visit (Visit 0) or a history of moderate or severe hypertension.
-
Participant has a known history of symptomatic cardiovascular disease, unexplained syncope, exertional chest pain, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems placing them at increased vulnerability to the sympathomimetic effects of a stimulant drug.
-
Participant is taking any medication that is excluded per the protocol.
-
Participant had any clinically significant electrocardiogram (ECG) or clinical laboratory abnormalities at the Screening Visit (Visit -1) or baseline visit (Visit 0), based on investigator judgment.
-
Participant has a history of hyperthyroidism, or current abnormal thyroid function, defined as abnormal thyroid stimulating hormone (TSH) and thyroxine (T4) at the Screening Visit (Visit-1) or Visit 0. Treatment with a stable dose of thyroid medication for at least 3 months is permitted.
-
Participant has taken another investigational product or has taken part in a clinical study within 30 days prior to the Screening Visit (Visit -1).
-
Participant is well-controlled on his/her current ADHD medication with acceptable tolerability.
-
Participant has glaucoma.
-
Participant has failed to fully respond, based on investigator judgment, to an adequate course of amphetamine therapy.
-
Participant has a current, controlled (requiring medication or therapy) or uncontrolled, comorbid psychiatric disorder including but not limited to any of the below co-morbid Axis I disorders and Axis II disorders:
- post-traumatic stress disorder (PTSD) or adjustment disorder
- bipolar illness, psychosis, or family history of these disorders
- pervasive developmental disorder
- obsessive-compulsive disorder (OCD)
- psychosis/schizophrenia
- participant has a serious tic disorder, or a family history of Tourette's disorder
- participant is currently considered a suicide risk in the opinion of the investigator, has previously made a suicide attempt, or has a prior history of, or is currently demonstrating active suicidal ideation. Participants with intermittent passive suicidal ideation are not necessarily excluded based on the assessment of the investigator
- a history of physical, sexual, or emotional abuse
- any other disorder or agitated state that in the opinion of the investigator, contraindicates SPD489 or lisdexamfetamine dimesylate treatment or confound efficacy or safety assessments.
-
Participant has initiated behavioral therapy within 1 month of the baseline visit (Visit 0). Participant may not initiate behavioral therapy during the study.
-
Participant has a height <=5th percentile for age and sex at the screening visit (Visit -1).
-
Participant has a weight <=5th percentile for age and sex at the screening visit (Visit -1).
-
Participant lives with anyone who currently abuses stimulants or cocaine.
-
Participant has a history of seizures (other than infantile febrile seizures).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description SPD489 SPD489 Participants will receive 5 milligrams (mg) of SPD489 capsule orally once daily in the morning and titrated in a step-wise fashion up to either 10 mg, 15 mg, 20 mg, or 30 mg until an optimal dose was reached within 52 weeks.
- Primary Outcome Measures
Name Time Method Number of Participants With Treatment-Emergent Adverse Events (TEAEs) From start of study drug administration up to follow-up (Week 53) An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs was defined as AEs that start or deteriorate on or after the date of the first dose of investigational product and no later than 3 days following the last dose of investigational product.
Change From Baseline in Sleep Patterns Assessed by Children's Sleep Habits Questionnaire (CSHQ) at Week 52/ Early Termination (ET) Week 52/ET Sleep patterns included sleep diary data and children's sleep habits questionnaire (CSHQ), which was parent report questionnaire designed to screen for the most common sleep problems in children, and consisted of 33 items for scoring and several extra items intended to provide administrators with other potentially useful information about respondents. The instrument evaluates the child's sleep based on behavior within 8 different sub scales: bedtime resistance, sleep-onset delay, sleep duration, sleep anxiety, night wakings, parasomnias, sleep-disordered breathing, and daytime sleepiness. Each item receives a score from 1 (problem occurs rarely) to 3 (problem usually occurs); therefore, a higher score is the worse outcome. Scale ranges are as follows: bedtime resistance: 6 to 18, sleep onset delay: 1 to 3, sleep duration: 3 to 9, sleep anxiety: 4 to 12, night walkings: 3 to 9, parasomnias: 7 to 21, sleep-disordered breathing: 3 to 9, and daytime sleepiness: 8 to 24.
Number of Participants With Potentially Clinically Significant Changes in Electrocardiogram (ECG) Parameters at Week 52/ Early Termination (ET) Week 52/ET 12-lead ECG was evaluated and recorded. ECG variables included heart rate, PR interval, QRS interval, QT interval, and corrected QT interval (QTc). The QTc was calculated using both Bazett (QTcB=QT/\[RR\]1/2) and Fridericia (QTcF=QT/\[RR\]1/3) corrections. Here, \> = represents "greater than or equal to", \< represents "lesser than" and \> represents "greater than".
Number of Participants With a Positive Response Using Columbia Suicide Severity Rating Scale (C-SSRS) at Week 52/ Early Termination (ET) Week 52/ET C-SSRS was semi-structured interview that captured the occurrence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview included definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behavior occurred. The C-SSRS contained 2 required items pertaining to suicidal ideation, 4 required items pertaining to suicidal behavior, and 1 required item pertaining to non-suicidal but self-injurious behavior. In situations where there was a positive response to the screening questions, there were 8 additional suicidal ideation items and 4 additional suicidal behavior items which were completed. Thus, there was a maximum of 19 items to be completed. Here number of participants responded as yes to suicidal ideation or behaviour were reported.
Number of Participants With Potentially Clinically Significant Changes in Clinical Laboratory Values at Week 52/ Early Termination (ET) Week 52/ET Clinical laboratory evaluations included biochemistry and endocrinology, hematology, and urinalysis. Number of participants with potentially clinically significant changes in clinical laboratory values were reported.
Number of Participants With Potentially Clinically Significant Changes in Vital Signs at Week 52/ Early Termination (ET) Week 52/ET Vital sign assessments included blood pressure, pulse and respiratory rate. Number of participants with potentially clinically significant changes in vital signs were reported.
Number of Participants With Shift From Baseline in Body Mass Index (BMI) Percentiles at Week 52/Early Termination (ET) Week 52/ET BMI was derived from height and weight. BMI was normalized by sex and age using the CDC growth charts. BMI percentiles were categorized as: Underweight (BMI \< 5th percentile); Healthy weight (BMI 5th percentile up to \< 85th percentile); Overweight (BMI 85th percentile \< 95th percentile); Obese (BMI \>= 95th percentile). Number of participants with shift from baseline in BMI percentile categories at Week 52/ET was reported.
- Secondary Outcome Measures
Name Time Method Clinical Global Impressions Global Improvement (CGI-I) at Week 52/ Early Termination (ET) Week 52/ET CGI-I was an overall assessment of global symptom improvement by evaluation of the participant's condition severity and improvement over time. Scoring was done based on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse), where higher score reported worse condition. The scoring was elaborated as: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse.
Change From Baseline in Clinician-Administered Attention-Deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV) Preschool Version Total Score at Week 52/ Early Termination (ET) Week 52/ET ADHD-RS-IV Preschool Version was adapted from the ADHD Rating Scale-IV and provided examples appropriate for the developmental level of preschool children. The ADHD-RS-IV Preschool Version was an 18-item questionnaire that required the respondent to rate the frequency of occurrence of ADHD symptoms as defined by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Text Revision (DSM-IV-TR) criteria. Each item was scored on a 4-point scale ranging from 0 (never or rarely) to 3 (very often) with total scores ranging from 0-54. The 18 items were grouped into 2 subscales: hyperactivity/impulsivity (even numbered items 2-18) and inattentiveness (odd numbered items 1-17).
Trial Locations
- Locations (50)
Harmonex, Inc
🇺🇸Dothan, Alabama, United States
iResearch Atlanta LLC
🇺🇸Decatur, Georgia, United States
Avail Clinical Research, LLC
🇺🇸DeLand, Florida, United States
Sarkis Clinical Trials
🇺🇸Gainesville, Florida, United States
Rochester Center for Behavioral Medicine
🇺🇸Rochester Hills, Michigan, United States
AVIDA
🇺🇸Newport Beach, California, United States
Pediatric Associates of Fairfield, Inc.
🇺🇸Fairfield, Ohio, United States
Washington University
🇺🇸Saint Louis, Missouri, United States
University Hospitals Case Medical Center
🇺🇸Cleveland, Ohio, United States
Elite Clinical Trials, Inc
🇺🇸Wildomar, California, United States
Jersey Shore University Medical Center (JSUMC)
🇺🇸Neptune, New Jersey, United States
Manhattan Behavioral Medicine
🇺🇸New York, New York, United States
Psychiatric Centers at San Diego
🇺🇸San Diego, California, United States
University of California
🇺🇸San Francisco, California, United States
Center For Psychiatry and Behavioral Medicine In
🇺🇸Las Vegas, Nevada, United States
Duke Child and Family Center
🇺🇸Durham, North Carolina, United States
University of Cincinnati
🇺🇸Cincinnati, Ohio, United States
Bayou City Research Limited
🇺🇸Houston, Texas, United States
BI Research Center
🇺🇸Houston, Texas, United States
Oklahoma Clinical Research Center
🇺🇸Oklahoma City, Oklahoma, United States
Paradigm Research Professionals
🇺🇸Oklahoma City, Oklahoma, United States
Cutting Edge Research Group
🇺🇸Oklahoma City, Oklahoma, United States
Red Oak Psychiatry Associates
🇺🇸Houston, Texas, United States
Road Runner Research
🇺🇸San Antonio, Texas, United States
Clinical Neurophysiology Services
🇺🇸Sterling Heights, Michigan, United States
Lake Charles Clinical Trials
🇺🇸Lake Charles, Louisiana, United States
Alliance for Wellness d/b/a Alliance for Research
🇺🇸Long Beach, California, United States
Sun Valley Research Center
🇺🇸Imperial, California, United States
Preferred Research Partners, Inc.
🇺🇸Little Rock, Arkansas, United States
Medical Research Group of Central Florida
🇺🇸Orange City, Florida, United States
Asclepes Research
🇺🇸Panorama City, California, United States
Kennedy Krieger Institute
🇺🇸Baltimore, Maryland, United States
University of South Florida
🇺🇸Saint Petersburg, Florida, United States
Premier Psychiatric Reseach Institute, LLC
🇺🇸Lincoln, Nebraska, United States
University of Rochester
🇺🇸Rochester, New York, United States
IPS Research Company
🇺🇸Oklahoma City, Oklahoma, United States
Rainbow Research Inc
🇺🇸Barnwell, South Carolina, United States
Carolina Clinical Trials, Inc.
🇺🇸Charleston, South Carolina, United States
Coastal Carolina Research
🇺🇸Mount Pleasant, South Carolina, United States
Clinical Neuroscience Solutions, Inc
🇺🇸Memphis, Tennessee, United States
BioBehavioral Research of Austin
🇺🇸Austin, Texas, United States
Cyn3rgy Research Center
🇺🇸Gresham, Oregon, United States
Family Psychiatry of the Woodlands
🇺🇸The Woodlands, Texas, United States
Northwest Clinical Research Center
🇺🇸Bellevue, Washington, United States
Ericksen Research and Development
🇺🇸Clinton, Utah, United States
Clinical Research Partners, LLC
🇺🇸Petersburg, Virginia, United States
Seattle Childrens Hospital
🇺🇸Seattle, Washington, United States
APG Research, LLC
🇺🇸Orlando, Florida, United States
Clinical Neuroscience Solutions
🇺🇸Orlando, Florida, United States
University of South Florida Department Of Psychiatry
🇺🇸Tampa, Florida, United States